

AMENDMENTS TO THE CLAIMS

1-28. **(Canceled)**

29. **(Previously Presented)** A method for ameliorating the effects of chronic inflammation in a subject which comprises administering an antibody specific for GM-CSF to the subject, for a time and in an amount to inhibit or otherwise antagonize the effects of GM-CSF on cells of the monocyte or macrophage lineage.

30. **(Previously Presented)** The method of Claim 29, wherein inhibiting or otherwise antagonizing the effects of GM-CSF on cells of the monocyte or macrophage lineage comprises reducing the level of proliferation, activation, growth and/or survival of cells of the monocyte or macrophage lineage.

31. **(Previously Presented)** The method of Claim 29 or 30, wherein said antibody antagonizes the effect of GM-CSF.

32. **(Previously Presented)** The method of Claim 29 or 30, wherein the antibody is identified through natural product screening or screening of a chemical library.

33. **(Previously Presented)** The method of Claim 29, wherein the antibody is internalized by the monocyte or macrophage cells.

34. **(Previously Presented)** The method of claim 29, wherein said administered antibody inhibits or otherwise antagonizes the effects of GM-CSF on cells of the monocyte lineage.

35. **(Canceled)**

36. **(Previously Presented)** The method of claim 29, wherein said antibody is a monoclonal antibody.

37. **(Previously Presented)** The method of claim 29, wherein said administered antibody inhibits or otherwise antagonizes the effects of GM-CSF on cells of the macrophage lineage.

38. **(Previously Presented)** The method of claim 29, wherein said subject is a human.

39. **(Previously Presented)** The method of claim 29, wherein said administered antibody inhibits or otherwise antagonizes the effects of GM-CSF on macrophage cells.

40. **(Previously Presented)** The method of claim 29, wherein said antibody is administered intravenously.

41. **(Previously Presented)** The method of claim 29, wherein said antibody is administered subcutaneously.

42. **(Currently Amended)** The method of claim 29, wherein the chronic inflammation is a chronic inflammation selected from the group consisting of rheumatoid arthritis, inflammatory bowel disease, Crohns disease, type I diabetes, multiple sclerosis, chronic inflammatory lung disease and psoriasis.

43. **(Previously Presented)** The method of claim 41, wherein the inflammation is a chronic inflammatory lung disease selected from the group consisting of asthma, chronic bronchitis, emphysema and chronic obstructive airway disease.

44. **(Previously Presented)** The method of claim 36, wherein said antibody is administered prophylactically.

45. **(Previously Presented)** The method of claim 29, further comprising co-administering to the subject one or more other compounds or molecules designed to reduce or alleviate any one or more symptoms of an inflammatory response.

46. **(Previously Presented)** The method of claim 45, wherein said one or more other compounds or molecules is administered simultaneously with said antibody specific for GM-CSF.

47. **(Previously Presented)** The method of claim 45, wherein said one or more other compounds or molecules is administered sequentially compared to said antibody specific for GM-CSF.

48. **(Previously Presented)** A method for ameliorating the effects of inflammation in a subject exhibiting inflammation, which comprises administering to said subject exhibiting inflammation an antibody specific for GM-CSF for a time and in an amount to inhibit or otherwise antagonize the effects of GM-CSF on cells of the monocyte or macrophage lineage.

49. **(Previously Presented)** The method of Claim 48, wherein inhibiting or otherwise antagonizing the effects of GM-CSF on cells of the monocyte or macrophage lineage comprises reducing the level of proliferation, activation, growth and/or survival of cells of the monocyte or macrophage lineage.

50. **(Previously Presented)** The method of Claim 48, wherein said antibody antagonizes the effect of GM-CSF.

51. **(Previously Presented)** The method of Claim 48, wherein the antibody is internalized by the monocyte or macrophage cells.

52. **(Previously Presented)** The method of claim 48, wherein said administered antibody inhibits or otherwise antagonizes the effects of GM-CSF on cells of the monocyte lineage.

53. **(Previously Presented)** The method of claim 48, wherein said antibody is a monoclonal antibody.

54. **(Previously Presented)** The method of claim 48, wherein said administered antibody inhibits or otherwise antagonizes the effects of GM-CSF on cells of the macrophage lineage.

55. **(Previously Presented)** The method of claim 48, wherein said subject is a human.

56. **(Previously Presented)** The method of claim 48, wherein said administered antibody inhibits or otherwise antagonizes the effects of GM-CSF on macrophage cells.

57. **(Previously Presented)** The method of claim 48, wherein said antibody is administered intravenously.

58. **(Previously Presented)** The method of claim 48, wherein said antibody is administered subcutaneously.

59. **(Previously Presented)** The method of claim 49, wherein the inflammation is a chronic inflammation selected from the group consisting of rheumatoid arthritis, inflammatory bowel disease, Crohns disease, type I diabetes, multiple sclerosis, chronic inflammatory lung disease and psoriasis.

60. **(Previously Presented)** The method of claim 59, wherein the inflammation is a chronic inflammatory lung disease selected from the group consisting of asthma, chronic bronchitis, emphysema and chronic obstructive airway disease.

61. **(Previously Presented)** The method of claim 48, further comprising co-administering to the subject one or more other compounds or molecules designed to reduce or alleviate any one or more symptoms of an inflammatory response.

62. **(Previously Presented)** The method of claim 61, wherein said one or more other compounds or molecules is administered simultaneously with said antibody specific for GM-CSF.

63. **(Previously Presented)** The method of claim 61, wherein said one or more other compounds or molecules is administered sequentially compared to said antibody specific for GM-CSF.

64. **(Previously Presented)** A method for ameliorating the effects of chronic inflammation in a subject in need of treatment for said chronic inflammation which comprises administering an antibody specific for GM-CSF to said subject for a time and in an amount to inhibit or otherwise antagonize the effects of GM-CSF on macrophage cells of the subject.